Drugs / BMSCs
BMSCs
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05850208 | Feb 2022 → Nov 2024 | ischemic stroke | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01468064 | Nov 2011 → Dec 2015 | middle cerebral artery infarction | Southern Medical University, China | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03969680 | Jul 2019 → Oct 2023 | osteoarthritis, knee | Yantai Yuhuangding Hospital | Terminated | No outcome recorded |
| — | NCT02177565 | Jan 2000 → Oct 2011 | — | Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02177565 ↗ |
| Known as | Bone Marrow Mesenchymal Stem Cells | “Autologous Bone Marrow Mesenchymal Stem Cells (BMSCs) Transplantation” NCT05850208 ↗ |
| Known as | bone marrow-derived mesenchymal stem cells | “autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP)” NCT03969680 ↗ |
| Modality | Cell therapy | “autologous transplantation of ex vivo expanded bone marrow stromal cells (BMSCs)and endothelial progenitor cells (EPCs) for treatment of patients with ischemic stroke” NCT01468064 ↗ |
| Route | Intravenous | “2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously” NCT01468064 ↗ |